Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 359

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

Open access
Schömig, Albert, Dibra, Alban, Windecker, Stephan, Mehilli, Julinda, Suárez de Lezo, José, Kaiser, Christoph, Park, Seung-Jung, Goy, Jean-Jacque, Lee, Jae-Hwan, Di Lorenzo, Emilio, Wu, Jinjin, Jüni, Peter, Pfisterer, Matthias E., Meier, Bernhard, Kastrati, Adnan · 2007 · Journal of the American College of Cardiology

Abstract

OBJECTIVES Our purpose was to make a synthesis of the available evidence on the relative efficacy and safety of 2 drug-eluting stents (DES)--sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)--in patients with coronary artery disease. BACKGROUND It is not known whether there are differences in late outcomes between the 2 most commonly used DES: SES and PES. METHODS Sixteen randomized trials of SES versus PES with a total number of 8,695 patients were included in this meta-analysis. A full set of individual outcome data from 5,562 patients was also available. Mean follow-up period ranged from 9 to 37 months. The primary efficacy end point was the need for reintervention (target lesion revascularization). The primary safety end point was stent thrombosis. Secondary end points were death and recurrent myocardial infarction (MI). RESULTS No significant heterogeneity was found across trials. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.63 to 0.87, p < 0.001) and stent thrombosis (HR 0.66; 95% CI 0.46 to 0.94, p = 0.02) without significantly impacting on the risk of death (HR 0.92; 95% CI 0.74 to 1.13, p = 0.43) or MI (HR 0.84; 95% CI 0.69 to 1.03, p = 0.10). CONCLUSIONS Sirolimus-eluting stents are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis. The risk of death was not significantly different between the 2 DES, but there was a trend toward a higher risk of MI with PES, especially after the first year from the procedure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2007.06.047

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 359

Metadata

Authors
Schömig, A., Dibra, A., Windecker, S., Mehilli, J., Suárez de Lezo, J., Kaiser, C., Park, S.-J., Goy, J.-J., Lee, J.-H., Di Lorenzo, E., Wu, J., Jüni, P., Pfisterer, M. E., Meier, B., & Kastrati, A.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2007-10
Volume
50
Issue
14
Pages
1373-1380
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2060153501
Cited by
359
References
32
FWCI
6.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. https://app.cochat.ai/papers/10.1016/j.jacc.2007.06.047
The paper
Schömig, A., Dibra, A., Windecker, S., Mehilli, J., Suárez de Lezo, J., Kaiser, C., Park, S.-J., Goy, J.-J., Lee, J.-H., Di Lorenzo, E., Wu, J., Jüni, P., Pfisterer, M. E., Meier, B., & Kastrati, A. (2007). A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2007.06.047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.